WIXOM, Mich., March 5, 2014 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, announced today that it will host a Key Opinion Leader Breakfast on Thursday, March 6, 2014, beginning at 8:00am Eastern Time, in New York City. Rockwell’s management team will provide a brief overview of the Company’s strategies to drive long-term growth, and Key Opinion Leader, Anatole Besarb, MD, will discuss how Rockwell’s Triferic™, currently under investigation for the treatment of iron replacement in dialysis patients, will play an integral role in the anemia and renal space.
Help employers find you! Check out all the jobs and post your resume.
